Neuroinflammation
Description
Neuroinflammation encompasses the immune responses within the central nervous system, primarily mediated by microglia and astrocytes, that become chronically activated in Alzheimer's disease. Unlike acute inflammation that resolves after clearing a threat, neuroinflammation in AD becomes self-perpetuating: damaged neurons release DAMPs (damage-associated molecular patterns) that activate microglia, which release pro-inflammatory cytokines (TNF-alpha, IL-1beta) that further damage neurons, creating a vicious cycle.
In the AD brain, neuroinflammation operates through multiple distinct but interconnected pathways. Microglial activation via TREM2 and TLR4 signaling produces inflammatory mediators that directly inhibit neuronal v-ATPase function, linking immune activation to autophagic collapse. The NLRP3 inflammasome, activated by lysosomal rupture and crystalline amyloid, amplifies IL-1beta release. Complement cascade components (C1q, C3, C4d) tag synapses for microglial phagocytosis, driving synapse loss independently of direct amyloid toxicity. Meanwhile, tau-induced reactivation of transposable elements produces dsRNA that mimics viral infection, triggering Type I interferon responses through sterile viral mimicry.
A paradigm shift is emerging: rather than viewing neuroinflammation as uniformly destructive, multiple prize entrants distinguish between harmful resident microglial inflammation and potentially protective peripheral immune responses. This reframing has profound therapeutic implications, suggesting that breaking systemic immune exhaustion -- rather than broadly suppressing inflammation -- may be the correct immunological strategy.
Convergence Nodes
- Neuroimmune Interface -- Complement-mediated synaptic pruning and TREM2 signaling as central immune effectors
- Cytoskeletal Collapse Node -- Complement deposition triggers dendritic spine elimination
- Transcriptional-Epigenetic Dysregulation Node -- Inflammatory signaling activates transcriptional programs that lock in pathological gene expression
Prize Entrants
- Donald Weaver -- Reclassified Abeta as an innate immune cytokine and antimicrobial peptide; proposed AD as autoimmune disorder of innate immunity
- Michal Schwartz -- Demonstrated systemic immune exhaustion in AD and proposed PD-L1 checkpoint blockade to recruit protective monocyte-derived macrophages
- Bess Frost -- Discovered sterile neuroinflammation via tau-induced transposable element reactivation producing dsRNA viral mimics
- Zhen Huang -- Showed Abeta monomer depletion disinhibits microglial TNF-alpha release, directly poisoning v-ATPase
- Li-Huei Tsai -- Demonstrated 40Hz gamma entrainment transforms microglia to phagocytic state, enhancing clearance
- Brenda Aske -- Described the LDAM-to-A1 astrocyte glial relay amplifying neuroinflammation through lipid-burdened microglia
- Carlo Abbate -- Linked chronic microglial Abeta activation to reactive neurogenesis, creating pathological tau-bearing neuroblasts
- Ralph Nixon · Maxim Shokhirev · Jeevan Pradhan · Richelle Cutler
External Scientists
- Michael Heneka -- Defined NLRP3 inflammasome activation in AD
- David Holtzman -- TREM2-ApoE axis in microglial function
- Marco Colonna -- TREM2 biology and microglial states
- Oleg Butovsky -- Microglial heterogeneity and disease-associated microglia (DAM)
- Shane Liddelow -- A1 neurotoxic astrocyte conversion
Key Open Questions
- Is neuroinflammation primarily a driver or an amplifier of AD pathology, and does this differ across disease stages?
- Can protective peripheral immune responses be selectively enhanced while dampening destructive resident microglial inflammation?
- How does the temporal sequence of inflammatory activation (Shokhirev's data showing immune activation as a late-stage event) reconcile with genetic evidence implicating immune genes as early risk factors?
- Does sterile viral mimicry from transposable element reactivation represent a major unrecognized inflammatory driver?
kb/wiki/concepts/neuroinflammation.md